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Abstract
Objectives: To estimate the health-adjusted life expectancy (HALE) from diabetes mellitus (DM)
using a population health survey linked to a population-based DM registry.
Methods: The 1996/97 Ontario Health Survey (N = 35,517) was linked to the Ontario Diabetes
Database (N = 487,576). The Health Utilities Index (HUI3) was used to estimate health-related
quality of life. HALE was estimated using an adapted Sullivan method.
Results: Life expectancy at birth of people with DM was 64.7 and 70.7 years for men and women
– 12.8 and 12.2 years less than for men and women without DM. The HUI3 was lower for
physician-diagnosed DM compared to self-reported DM (0.799 versus 0.872). HALE at birth was
58.3 and 62.8 years for men and women – 11.9 and 10.7 years less than that of men and women
without DM.
Conclusions: The linked data approach demonstrates that DM is an important cause of disease
burden. This approach reduces assumptions when estimating the prevalence and severity of
disability from DM compared to methods that rely on self-reported disease status or indirect
assessment of disability severity.
Background
Summary measures of population health (SMPH) [1],
which take into account both mortality and morbidity,
fall into two major classes: positive measures of health
expectancy [2] such as health-adjusted life expectancy
(HALE) [3,4], and measures of health gaps such as loss of
healthy life years [5] or disability-adjusted life years
(DALYs) [6]. Health expectancy, which is the focus of this
study, represents life expectancy adjusted according to the
amount of time spent in less than perfect health or with
disability.
Three data components are needed to estimate all types of
SMPH for specific conditions: mortality attributed to the
condition; the prevalence or incidence and duration of the
condition; and the degree to which health-related quality
of life (HRQOL) is affected. While all SMPH commonly
use the same source of mortality information, namely
vital statistics, there are differences in how other compo-
nents are measured. Health expectancy measures typically
estimate the impact of chronic conditions on HRQOL
from population-based health surveys. However, attribut-
ing HRQOL to different chronic diseases in population
health surveys is difficult since self-reports of chronic
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disease status often underestimate the prevalence of many
chronic conditions [7-11]. The best estimates of disease
incidence or prevalence are achieved through population-
based epidemiologic studies or disease registries, a
method of estimating disease occurrence often used by
health gap measures such as DALYs [6]. However, health
gap measures also regularly use measures of HRQOL that
have disability weights or levels of disabilities that are
assigned by informed consumers, expert opinion or other
epidemiologic sources that may not reflect the observed
impact in specific populations.
In this study, we estimated HALE for people with diabetes
mellitus (DM) in Ontario, Canada in 1996 to 1997 using
a population health survey that was directly linked to a
DM registry. This linkage overcomes the limitations of
previous estimates of both health gaps and health expect-
ancy by directly measuring both disease prevalence and
HRQOL impact without relying on self-reported disease
status or case scenarios of HRQOL that may not reflect the
actual HRQOL of people with DM in Ontario.
Methods
Data sources
Cross-sectional data on HRQOL were derived from the
1996/97 Ontario Health Survey (OHS II) [12]. The
Ontario Ministry of Health sponsored Statistics Canada to
augment the Ontario sample of the 1996/97 National
Population Health Survey (NPHS) to be able to produce
reliable local-level estimates. 48,770 households were
selected through stratified, multi-level cluster sampling of
all private dwellings in Ontario, with local planning
regions as the primary sampling unit. Residents of Indian
reserves, long-term care institutions, prisons, remote areas
and Foreign Service personnel were excluded. Respond-
ents were contacted in person at their dwelling or by tele-
phone. The actual survey was a telephone interview with
two components, with data collection occurring between
October 1996 and August 1997. A general component
collected limited information on all members of the
household; household response rate was 77.5%, or
37,796 households. The second component, which was
the component used in this study, was administered to
one randomly selected member from each survey house-
hold. The number of respondents who agreed to share
their survey information with the provincial Ministry of
Health was 37,247, a response rate of 98.5%. A further
subgroup of survey respondents agreed to allow their sur-
vey responses to be linked to health care data; however, of
the 35,517 (96.3%) who agreed to this, only 23,403
(65.6%) were linked to the central health administrative
registry (the Registered Persons Database (RPDB), dis-
cussed later in this section) due to a technical difficulty
resulting in missing OHS II demographic information.
This technical problem did not bias the linkage process
towards any particular group of respondents [13].
The OHS II, as part of the NPHS, was a two-stage proba-
bility sample. The final survey weight represents both the
selection probabilities and post-stratification adjustments
to match the sample to population characteristics [14]. A
new survey weight was calculated specifically for the link-
able portion of the survey. All analyses were weighted to
represent the Ontario population in 1996–1997. To
account for survey design effects, standard errors and coef-
ficients of variation were estimated with the bootstrap
technique [15-17].
Although the OHS II contained self-reported DM status,
in this study the DM status of survey respondents was
established by directly and individually linking them to
the Ontario Diabetes Database (ODD) (N = 487,576 in
1997). The ODD is a population-based disease registry
that was created through physician payment, hospital dis-
charge data and the RPDB. The ODD has been validated
in previous studies and found to be sensitive and specific
for identifying persons with physician-diagnosed DM
[18]. Approximately 95% of all people in Ontario who
have physician-diagnosed DM are identified in the ODD.
The algorithm used to create the ODD specified that any
patient with two physician service claims bearing a diag-
nosis of DM within a two-year period, or one hospitaliza-
tion with a diagnostic code for DM would be identified as
having DM [18,19]. Throughout this study we used this
physician-diagnosed definition of DM status, unless oth-
erwise noted, to estimate HRQOL, mortality, life expect-
ancy and health expectancy.
The third linked data source used in the study was the
RPDB, which contained basic demographic information
on all persons eligible for health insurance coverage in
Ontario. The RPDB is linked to vital statistics data col-
lected by the Office of the Registrar General (156,610
deaths among Ontario residents during 1996 and 1997),
thereby allowing for mortality estimates for people with
and without DM. Approximately 93% of vital statistics
deaths were linked to individual RPDP registrants. Age-
and sex-specific adjustments were applied to correct for
underestimation. Similar to other studies these all-cause
deaths were used to estimate life and health expectancy
for all Ontarians with and without DM [20-23]. Informa-
tion on the cause of death from vital statistics is not
known for people in RPDB. The death rate from DM as a
main underlying cause of death for all Ontarians was
obtained from Statistics Canada vital statistics data. The
post-censal population estimates for 1996 and 1997 for
each age and sex group were from Statistics Canada.Population Health Metrics 2004, 2 http://www.pophealthmetrics.com/content/2/1/4
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HRQOL Measure – The Health Utilities Index
The HRQOL measure used to calculate HALE in this study
was the Health Utilities Index Mark 3 (HUI3) [24]. The
HUI3 is a preference-based, multi-attribute health classifi-
cation system that estimates a summary value of individ-
ual health where 0.0 = "dead" and 1.0 = "perfect health"
(states worse than death are also possible), based on pref-
erence scores for different health states [25]. In many
ways, the HUI3 is similar to other generic measures of
HRQOL such as the Medical Outcomes Study 36-Item
Short Form (SF-36) or the EuroQol Instrument (EQ-5D)
[26,27]. The HUI3 focuses primarily on the "within the
skin" attributes of HRQOL, meaning the HUI3 aims to
capture physical and mental functioning, as opposed to
social participation [25,28,29]. Each OHS II respondent
answered questions pertaining to eight attributes of func-
tional health: vision, hearing, speech, mobility, dexterity,
emotional state, cognition and level of pain and discom-
fort. Each attribute has from 5 to 6 possible levels ranging
from unrestricted to a highly disabled state (see Torrance
et al. [30] or the Health Utilities Group website [31] for a
description of health states). The eight attributes are
assigned utility weights and combined to create a sum-
mary value.
The process to establish attribute values and combine
these values into a summary score involved a separate
study [28]. This study randomly selected respondents
from the general public. Respondents were asked to value
different health states using a visual analogue scale and
the standard gamble technique. The eight attributes were
then combined using preference scores from the HUI3
using the following multi-attribute utility function where
u is the utility for a chronic health state and b is single-
attribute utility score [32] :
u = 1.371 (b1 × b2 × b3 × b4 × b5 × b6 × b7 × b8) - 0.371
The scoring system has the potential to create over
972,000 unique health states. 1995 unique health states
were reported in respondents of the 1994/95 version of
the NPHS [28].
Analysis methods
Diabetes-deleted mortality rate and HUI3 estimates
DM-deleted mortality rates were calculated by subtracting
the mortality rate for people with physician-diagnosed
DM from the overall mortality rate for each age-sex group.
DM-deleted HUI3 was calculated in a similar manner by
removing all people with physician-diagnosed DM from
the OHS II sample and recalculating the mean HUI3 for
each age-sex group.
Life table analysis
Period life tables for 1996–1997 for men and women
were calculated using an adaptation of Chiang's method
[33] and 20 standard age-groups (<1 year, 1–4 years, 5–9
years, ..., 90 years and older), except for an adaptation for
the final age-group [34]. DM-deleted life expectancy was
calculated by substituting the physician-diagnosed DM-
deleted mortality rates for the overall mortality rates in the
life table [35]. HALE was calculated using a modified Sul-
livan method [36]. Sullivan used a period life table and
the prevalence of disability to estimate the number of life
years lived free of disability. After calculating life tables for
each group, HALE was estimated by weighting the years of
life lived according to the mean HUI3 values by age and
sex for each population. The physician-diagnosed DM-
deleted mean HUI3 values were used to calculate DM-
deleted HALE. Statistical errors for life expectancy and
HALE were calculated using the methods of Chiang and
Mathers, respectively [37,38]. See Appendix 1 for Excel life
tables used in this study.
Results
Table 1 compares methods for estimating DM status.
53.2% of people in the ODD (who had the disease diag-
nosed by a physician) reported that they did not have DM
[18]. Those in the ODD who also self-reported DM had an
HUI score that was lower than those who did not report
DM (0.799 versus 0.872), although the age-standardized
HUI3 estimates were similar. This suggests that the people
with physician-diagnosed DM who did not self-report DM
were younger and slightly healthier than people who
reported they had DM, possibly because they had the con-
dition for less time than people who reported they had
DM. This comparison illustrates how estimating HALE
using the HUI3 estimates for DM based on the ODD over-
comes the limitations of previous health expectancy esti-
mates that relied on self-reported DM status [23,39].
Table 2 shows the mean HUI3 score for people with DM
and the DM prevalence for different ages and health
states. The weights were compared to the World Health
Organization Global Burden of Disease (GBD) disability
weights [6]. The GBD disability weights are scaled simi-
larly to the HUI3 with death assigned a utility weight of 0
and 1 being perfect health. The GBD project assigned dif-
ferent weights for the complications of diabetic foot and
blindness. While this would have been possible in our
study for blindness and other complications, we instead
estimated the mean HUI3 score for men and women with
and without DM at different ages. We then assumed that
the impact of DM on HRQOL was the difference between
the mean HUI3 score for people with and without DM.
The overall HUI3 score for DM (0.896 and 0.886 for men
and women, respectively) was lower than the disability
weight for uncomplicated DM in the WHO projectPopulation Health Metrics 2004, 2 http://www.pophealthmetrics.com/content/2/1/4
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(0.967). Indeed, the HUI3 score was similar for the WHO
weight for diabetic foot (0.871). Since the overall preva-
lence of blindness in people with DM in this study was
0.1% and other complications such as diabetic foot are
uncommon [40], they would have a very small influence
in the overall DM HRQOL score in Ontario.
Table 3 shows mortality and HALE estimates for people
with and without DM. Almost one quarter of all people
who died in Ontario in 1996 and 1997 had DM (18,320
people per year). However, only 12.5% of the people who
died in Ontario had DM identified as the underlying cause
of death. The age-standardized death rate for people with
DM was over twice that of people without DM (1,369 per
100,000 for men with DM versus 588 for men without
DM; 1,315 per 100,000 for women with DM versus 533
for women without DM). This increased death rate trans-
lates into a life expectancy at birth 12.8 years less than for
men without DM and 12.2 years less than women without
DM. The estimates of life expectancy at birth combine the
Table 1: Diabetes status in the 1996/97 Ontario Health Survey II (OHS II) compared to the Ontario Diabetes Registry (ODD)
Physician diagnosed diabetes† (95% Confidence Interval)
Diabetes mellitus No diabetes mellitus
Self-reported 
diabetes 
status*
Diabetes 
mellitus
N (unweighted) 840 68 908
% (weighted) 46.8 0.25
Mean HUI3 (unadjusted, weighted) 0.799 (0.773 – 0.826) 0.862 (0.811 – 0.914)
Mean HUI3 (age-adjusted, weighted) 0.891 (0.865 – 0.917) 0.729 (0.678 – 0.780)
No diabetes 
mellitus
N (unweighted) 830 21,325 22,155
% (weighted) 53.2 99.8
Mean HUI3 (weighted) 0.872 (0.854 – 0.889) 0.917 (0.888 – 0.945)
Mean HUI3 (age-adjusted, weighted) 0.906 (0.889 – 0.923) 0.916 (0.888 – 0.944)
1,670 21,393 23,063
Sensitivity of self-reported DM = 46.8% Specificity of self-reported DM = 99.8% * Self-reported DM status from the 1996/97 Ontario Health 
Survey: "Do you have diabetes diagnosed by a health professional?" † DM status from the Ontario Diabetes Database (ODD) Abbreviations: DM 
diabetes mellitus, HUI3 Health Utilities Index Mark III
Table 2: Utility weights and prevalence estimates for diabetes mellitus from the ODD/OHS II* and the WHO Global Burden of Disease 
(GBD) study†
WHO Global Burden of Disease (both sexes combined)
Age group 
(yrs)
HUI3 (DM prevalence %‡) Treated (prevalence %‡) Not treated (prevalence unknown)
Men Women Un-
complicated 
DM
Diabetic foot Blindness Un-
complicated 
DM
Diabetic foot Blindness
12–39 0.940 (1.7) 0.932 (2.0) 0.967 (1.8) 0.871 (--) 0.507 (0.0) 0.989 0.863 0.400
40–54 0.915 (7.4) 0.897 (5.6) 0.967 (6.5) 0.871 (--) 0.507 (0.0) 0.989 0.863 0.400
55–69 0.870 (17.2) 0.855 (11.0) 0.967 (13.8) 0.871 (--) 0.507 (0.1) 0.989 0.863 0.400
70+ 0.775 (20.9) 0.778 (16.2) 0.967 (17.7) 0.871 (--) 0.507 (0.4) 0.989 0.863 0.400
Total 0.896 (7.0) 0.886 (5.8) 0.967 (6.3) 0.871 (--) 0.507 (0.1) 0.989 0.400 0.400
Abbreviations: DM diabetes mellitus, HUI3 Health Utilities Index Mark III *ODD/OHS II – the 1996/97 Ontario Health Survey linked to the Ontario 
Diabetes Database; utility weights are HUI3 scores †WHO Global Burden of Disease Study [6] – weights are based on expert opinion. ‡All 
prevalence estimates are from the OHS IIPopulation Health Metrics 2004, 2 http://www.pophealthmetrics.com/content/2/1/4
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experience of people who have diabetes for varying
lengths of time from early in life to older years. In addi-
tion, these estimates do not distinguish people with type
1 or 2 diabetes. The life expectancy at age 40 years (an age
at which type 2 diabetes becomes the more common) for
men with DM was 8.9 years less than for men without DM
and 10.2 years less than women without DM. Life expect-
ancy and HALE estimates for different age groups are
shown in the Appendix (see Additional file 1).
HALE at birth was 58.3 years for men with DM, compared
to 70.2 years for those without; and 62.7 years for women
with DM compared to 73.5 years for those without DM.
Given the present burden of disease, eliminating DM
would extend overall life expectancy at birth in Ontario by
2.7 years, and would extend HALE by 3.2 years (Table 4).
Discussion
This study used linked databases containing population-
based mortality, morbidity and DM prevalence to esti-
mate life expectancy and HALE of people with and with-
out DM. People with DM have a much lower life
expectancy and HALE than people without DM. Further-
more, the life expectancy and HALE of the entire popula-
tion would be substantially higher if DM were eliminated,
demonstrating that DM is an important burden of disease
in the Ontario population.
It is important not only to add "years to life", but also to
add "life to years", meaning improvements in life expect-
ancy should ideally be accompanied by improvements in
HRQOL [41]. Efforts to prevent diseases that are fatal will
add "years to life"; while reducing the prevalence of dis-
eases that affect HRQOLwill add "life to years". DM has
about the same impact on HRQOL as mortality in men
and a larger HRQOL impact in women, suggesting that
reducing or eliminating the disease has the potential to
"compress morbidity" – meaning extra years of life would
be lived in a state of improved HRQOL. This is in contrast
to the impact of a reduction in the incidence of conditions
that have a higher mortality burden than HRQOL burden,
such as cancer, which has been predicted to cause an
"expansion of morbidity", since people would live longer
but in poorer health due to the onset of other conditions
such arthritis [39,42].
It is worth highlighting a few of the advantages of using
linked databases when estimating SMPH. Disease regis-
tries that are linked to a current population health survey
are well suited to measure morbidity from different con-
ditions, as health surveys directly estimate the health sta-
tus of a population at a defined time period. Health
surveys that are repeated over time can monitor the
progress of reducing morbidity in populations. These
prevalence-based estimates of HRQOL for specific condi-
tions yield the combined effect of duration and severity of
disease along with the impact of health interventions or
other health improvements. As the typical estimation of
SMPH in the GBD usually uses different sources of infor-
mation for each of these disease properties, their methods
may have difficulty reflecting differences in the HRQOL
impact of diseases in different populations and time peri-
ods. For an example of these differences, consider what
would happen to HRQOL if a new DM medication was
introduced that dramatically improved HRQOL. A popu-
lation-based health survey would capture the current
Table 3: Mortality, life expectancy and health-adjusted life expectancy (HALE) for people with and without diabetes mellitus (DM), 
Ontario, Canada, 1996–1997
Men (95% confidence interval) Women (95% confidence interval)
Without DM With DM Rate Ratio Without DM With DM Rate Ratio
Population, 1997 5,365,891 232,553 5,513,006 216,658
Deaths, all-cause 
(per year)
31,022 9,646 29,900 8,750
Crude death Rate  
(per 100,000)
580 (572 – 585) 4,150 (4,065 – 4,231) 7.2 (6.6–7.9) 542 (536 – 548) 4,039 (3,954 – 4,123) 7.4 (6.8 – 8.1)
Age-adjusted 
death rate (per 
100,000)
588 (582 – 595) 1,369 (1,299 – 1,438) 2.3 (2.1 – 2.6) 533 (527 – 539) 1,315  (1,272 – 1,357) 2.5 (2.3 – 2.8)
Difference Difference
Life expectancy at 
birth (years)
77.5 (77.4 – 77.6) 64.7 (63.0 – 66.4) 12.8 (11.1 – 14.5) 82.9 (82.9 – 83.0) 70.7 (69.9 – 71.5) 12.2 (11.4 – 13.0)
HALE at birth 
(years)
70.2 (70.2 – 70.5) 58.3 (56.3 – 60.3) 11.9 (9.9 – 13.9) 73.5 (73.2 – 73.7) 62.7 (61.4 – 64.1) 10.7 (9.3 – 12.1)
HALE/life 
expectancy ratio
0.91 0.90 0.89 0.89Population Health Metrics 2004, 2 http://www.pophealthmetrics.com/content/2/1/4
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improvement. GBD DALYs, as commonly derived, would
require further epidemiologic studies and expert opinion
to readjust disability weights for treated people with DM
and estimate the proportion of people treated with the
new intervention. As there are many factors affecting dis-
ease morbidity in different populations that are con-
stantly changing over time – such as socioeconomic
conditions, physical and social environment, medical
therapies, and health risk behaviour – it would seem
unlikely that the current GBD approach could reflect the
actual disease morbidity burden in any specific
population.
Furthermore, since our linked databases include health
administrative information about people who receive dif-
ferent health interventions (drug prescribing, physician
consultations, hospital admissions, etc.), it may be possi-
ble to assess the health impact of specific interventions on
the people who received those interventions [43,44], or
the total population [45].
An important limitation of this study is the omission of
residents of long-term care facilities in the morbidity data
used in the calculation of HRQOL impact. Berthelot and
colleagues have shown that including these people would
reduce population HRQOL utility estimates by up to 30%
for women in the oldest age groups [46]. On the basis of
their findings, the overall HALE estimates would be about
0.6 to 0.8 years lower if institutionalised people were
included (calculations not shown). The bias resulting
from excluding this population may be higher for condi-
tions such as DM, which may be over-represented in
institutions.
Health expectancy measures have been criticized because
they are prevalence-based, which makes them less suited
to monitoring trends in disease occurrence and the impact
of disease prevention on future health [47,48]. Because
the DM registry used in this study contains information
on disease incidence, prevalence and duration of disease,
and age of death, it is possible to estimate the changing
HRQOL impact over time and age based on either disease
incidence or prevalence, thereby opening novel opportu-
nities to improve estimates of summary measures (includ-
ing health gap, health expectancy or hybrid measures) by
considering the effect of changing disease incidence on
future HRQOL [48].
An additional benefit of using linked data and population
health surveys is the ability to adjust summary measure
estimates for comorbidity (defined as the effect of a per-
son's HRQOL being influenced by other chronic condi-
tions) by various methods [39]. In this study, we adjusted
for comorbidity by assuming the HRQOL burden of DM
is equal to the difference in HRQOL between people with
and without DM at the same age and sex. This method
assumes that if DM were eliminated, the HRQOL would
improve to the level of the remaining population, many
of whom have other conditions. Although DALYs have
been estimated considering co-morbidity, this is not usu-
ally done [37]. In the usual GBD approach, it is assumed
that if DM were eliminated, people would have no disa-
bility at all – a situation that is particularly unlikely in
older ages.
Finally, our method creates a tight association between
the measurement of disease, HRQOL and mortality. The
typical GBD method often defines different disability
weights for different severities of disease, but these sever-
ity groups may not be congruent with the measurement of
disease incidence. For example, if the definition of disease
used to measure disease incidence is broad, thereby
capturing people with mild disease, but the disability
weight used is based on more severe disease, then the bur-
den of disease will be overestimated. Such definitional
differences have been reduced in our study because
HRQOL is measured for people within the same disease
registry used to estimate disease incidence and prevalence
[42].
The increased mortality ratio in this study was similar to
that observed in other populations [49]. Consequently,
we observed a life expectancy difference between people
with and without DM that was similar to other studies
Table 4: Life expectancy (LE) and health-adjusted life expectancy (HALE) at birth for Ontario, Canada, 1996–1997, before and after 
eliminating diabetes mellitus (DM)
Expectancies at birth Men (95% confidence interval) Women (95% confidence interval)
Life expectancy before eliminating DM (years) 76.2 (76.1 – 76.2) 81.4 (81.3 – 81.5)
HALE before eliminating DM (years) 68.9 (68.7 – 69.2) 72.2 (71.9 – 72.5)
DM-eliminated LE (years) 78.9 (78.8 – 79.0) 84.1 (84.0 – 84.1)
DM-eliminated HALE (years) 71.6 (71.3 – 71.9) 75.4 (75.1 – 75.7)
Gain in LE (years) 2.8 (2.7 – 2.9) 2.6 (2.5 – 2.8)
Gain in HALE (years) 2.7 (2.3 – 3.1) 3.2 (2.8 – 3.6)Population Health Metrics 2004, 2 http://www.pophealthmetrics.com/content/2/1/4
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[20-22]. Care should be taken when making inferences
from life expectancy estimates. Period life table estimates
are summary descriptive measures created from cross-sec-
tional data of open populations with a main assumption
a stationary or steady-state population. This means that
life expectancy for people with DM is estimated using peo-
ple with varying time lengths of exposure to diabetes – in
the same way that life expectancy of a country includes
immigrants to that country, with a differing length of
exposure to that county's health risks. In practical terms,
estimates in this study should not be used to "predict" life
expectancy, but instead to describe the mortality and
health experience of people with and without DM. Simi-
larly, a limitation of this study was the inability to differ-
entiate type 1 and type 2 DM. The onset of illness is earlier
for type 1 DM, therefore, the cumulative impact of type 1
DM on individual health is likely greater than for type 2
DM. However, the impact of DM on population health is
strongly influenced by type 2 DM because it is much more
prevalent than type 1 DM.
The cause-deleted life table approach assumes that if DM
were eliminated the mortality rate and HRQOL burden
for people who had DM would be the same as those with-
out DM. It is possible that people with DM have a higher
mortality rate or HRQOL burden from causes that are not
directly related to DM – i.e. health behaviour such as
hypertension and obesity – thereby resulting in our study
overestimating of the population impact of DM. How-
ever, it should be noted that reduction in illness from
these non-DM-related conditions may also be achieved if
the prevalence of DM is reduced through health promo-
tion or disease prevention that targets common risk fac-
tors for other disease. Therefore, reducing DM through
these methods would potentially exceed the gains in life
expectancy and HALE that we report. Vital statistics have
been found to be a challenging data source to use for DM
mortality studies since many DM deaths are identified as
other conditions as the "underlying cause of death" [49].
Similar to other jurisdictions, Canada has begun system-
atically recording multiple causes of death, which will
open opportunities to adjust for co-morbid conditions for
mortality estimates in future studies.
There are limitations when estimating SMPH using infor-
mation from population health surveys. Although there
are at least 50 countries that have now conducted popula-
tion health surveys, they are neither routinely repeated
over time, nor easily comparable between populations
and seldom have provisions for linkages to other data
sources [50]. The latter omission makes it particularly dif-
ficult to apply the methods presented in this study in
other jurisdictions. However, population health surveys
linked to administrative data or disease registries can be
an accurate method of ascertaining disease status and
therefore provide a useful method of estimating popula-
tion-based HRQOL for persons with chronic conditions
such as DM. As such, they could be used to enhance and
improve the estimates of the more subjective disability
assignment and incidence or prevalence estimation exer-
cises. The disability weights project in the Netherlands
used health surveys and other sources to improve disabil-
ity weights for their country and those improved disability
weights have been used in other countries [51]. The
approach used in this study is not well suited for acute
conditions or other chronic conditions that cannot be
accurately identified in population health surveys or
linked registries and health care data.
This study has demonstrated that linked databases con-
taining HRQOL and prevalence information can be used
to estimate the large combined mortality and morbidity
burden of diabetes. This is important, since there is a com-
mitment in Ontario for regular routine large population
health surveys (every two years with a sample size
>40,000 respondents), so it will be possible to monitor
progress in reducing the burden of diabetes and other dis-
eases. With the approach of this study we can potentially
measure the progress of reducing the large burden of dis-
ease from DM.
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